Sector
PharmaceuticalsOpen
₹36.5Prev. Close
₹42Turnover(Lac.)
₹0.39Day's High
₹41.36Day's Low
₹36.552 Week's High
₹55.0252 Week's Low
₹31.5Book Value
₹-7.21Face Value
₹10Mkt Cap (₹ Cr.)
14.61P/E
0EPS
0Divi. Yield
017 Sep 2024
12:00 AM
AGM
Announcement Date: 17 Sep, 2024
21 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 4.45 | 4.45 | 4.45 | 4.45 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -4.38 | 1.4 | 1.51 | 1.37 |
Net Worth | 0.07 | 5.85 | 5.96 | 5.82 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 20.91 | 11.9 | 0 | 0 |
yoy growth (%) | 75.77 | 0 | 0 | |
Raw materials | -11.26 | -5.78 | 0 | 0 |
As % of sales | 53.85 | 48.57 | 0 | 0 |
Employee costs | -2.91 | -2.13 | -0.01 | 0 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | 0.73 | 0 | 0 | 0.01 |
Depreciation | -1 | -1.09 | 0 | 0 |
Tax paid | -0.3 | 0 | -0.01 | -0.01 |
Working capital | -0.24 | -2.57 | 0.01 | |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 75.77 | 0 | 0 | |
Op profit growth | 63.49 | -2,069.75 | 12.91 | |
EBIT growth | 2,335.31 | 587.94 | -55.19 | |
Net profit growth | 78,904.6 | -106.88 | 108.03 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,682.05 | 94.39 | 4,03,580.14 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,783.05 | 81.52 | 1,80,068.67 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484.6 | 24.91 | 1,19,918.75 | 1,485.4 | 1.08 | 4,254.47 | 397.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,407.05 | 60.94 | 1,15,304.87 | 474 | 0.18 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,699.8 | 59.14 | 1,11,428.51 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Umang Alkesh Gosalia
Non-Exec. & Independent Dir.
Ami R Shah
Non-Exec. & Independent Dir.
Nikhil S. Uchat
Plot No 20 Survey No 52,
Tal Kotda Sangani Hadamtala,
Gujarat - 360311
Tel: 91-2827-270534/535
Website: http://www.parmaxpharma.com
Email: info@parmaxpharma.com
9 ShivShakti Indl Es,
J R Boricha Marg, Lower Parel,
Mumbai - 400 011
Tel: 91-22-23016761/8261
Website: -
Email: -
Summary
Incorporated in Nov.94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufactur...
Read More
Reports by Parmax Pharma Ltd
What is the Parmax Pharma Ltd share price today?
What is the Market Cap of Parmax Pharma Ltd?
What is the PE and PB ratio of Parmax Pharma Ltd?
What is the 52 Week High and Low of Parmax Pharma Ltd?
What is the CAGR of Parmax Pharma Ltd?
What is the shareholding pattern of Parmax Pharma Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.